Antifungal Drug Susceptibility and Genetic Characterization of Fungi Recovered from COVID-19 Patients
Open Access
- 11 July 2021
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (7), 552
- https://doi.org/10.3390/jof7070552
Abstract
Fungal infections are common complications of respiratory viral infections and are associated with the increased need for intensive care and elevated mortality. Data regarding microbiological and molecular characteristics of such infections in COVID-19 patients are scarce. Here, we performed a comprehensive analysis, including species identification, antifungal susceptibility testing, molecular resistance determinants analysis, typing, and retrospective clinical data review, of fungal isolates recovered from 19 COVID-19 patients, who were hospitalized at the Hackensack University Medical Center (HUMC) in Hackensack, New Jersey, USA, in the initial phase of the pandemic from April–May 2020. In total, 17 Candida albicans, two C. parapsilosis, and two Aspergillus fumigatus were analyzed. All Candida spp. isolates were susceptible to micafungin and azole drugs (fluconazole, voriconazole, posaconazole, itraconazole, isavuconazole). A. fumigatus isolates were susceptible to micafungin and all triazole drugs except fluconazole (intrinsic resistance). Multilocus sequence typing (MLST) of C. albicans isolates revealed 15 different sequence types (STs), which clustered below the clade-defining limit of p-distance < 0.04. Pulsed-field gel electrophoresis (PFGE) karyotyping revealed no chromosomal rearrangements in these isolates. A. fumigatus isolates were of different, non-related genotypes. We speculate that virus- and drug-induced immunosuppression (94.7% of the patients received corticosteroids), together with prolonged hospital stay (median duration of 29 days) and mechanical ventilation (median duration of 24 days) likely increased the susceptibility to secondary respiratory and bloodstream infections in the studied patient population. The presence of fungi in blood or respiratory tract fluid was a prognosticator for poor clinical outcome, which presented as an 89.5% 30-day mortality in our patient cohort.Keywords
Funding Information
- Merck’s Investigator Studies Program (60453, DSP)
- CDI (COVID-19 Pilot Research Grant, COVID-19 Response)
This publication has 64 references indexed in Scilit:
- Secondary Bacterial Infections in Patients with Seasonal Influenza A and Pandemic H1N1BioMed Research International, 2013
- Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest MediaAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution MethodJournal of Clinical Microbiology, 2009
- Aneuploid Chromosomes Are Highly Unstable during DNA Transformation of Candida albicansEukaryotic Cell, 2009
- Evolution inCandida albicansPopulations During a Single Passage Through a Mouse HostGenetics, 2009
- A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin SusceptibilityAntimicrobial Agents and Chemotherapy, 2008
- Aspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based IdentificationAntimicrobial Agents and Chemotherapy, 2008
- Molecular Phylogenetics of Candida albicansEukaryotic Cell, 2007
- A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A AlterationsAntimicrobial Agents and Chemotherapy, 2007
- Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicansScience, 2006